UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes

Diabetes care, 2002-04, Vol.25 (4), p.724-730

2002

Volltextzugriff (PDF)

41-LB: Changes in Circulating Metabolites, Including Butyrate, Points to Underlying Mechanism of a Probiotic Intervention That Improves Postprandial Hyperglycemia in Subjects with Type 2 Diabetes

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2003-07, Vol.88 (7), p.3082-3089

2003

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

American journal of health-system pharmacy, 2005-01, Vol.62 (2), p.173-181

2005

Volltextzugriff (PDF)

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Diabetes care, 2003-03, Vol.26 (3), p.784-790

2003

Volltextzugriff (PDF)

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

Obesity (Silver Spring, Md.), 2004-04, Vol.12 (4), p.661-668

2004

Volltextzugriff (PDF)

Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy

Postgraduate medicine, 2013-05, Vol.125 (3), p.136-144

2013

Volltextzugriff (PDF)

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study

Diabetes care, 2003-11, Vol.26 (11), p.3074-3079

2003

Volltextzugriff (PDF)

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

Diabetes care, 2003, Vol.26 (1), p.1-8

2003

Volltextzugriff (PDF)

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

Diabetes technology & therapeutics, 2002, Vol.4 (1), p.51-61

2002

Volltextzugriff (PDF)

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

Diabetes/metabolism research and reviews, 2004-01, Vol.20 (1), p.55-60

2004

Volltextzugriff (PDF)

135-OR: A Novel Thiazolidinedione (TZD) with Minimal PPAR-γ Activity Maximized for Mitochondrial Pyruvate Carrier (MPC) Modulation: Six-Month Analysis of Glycemia in a 12-Month Nonalcoholic Steatohepatitis (NASH) Study

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

2046-P: NS-0200 (Leucine-Metformin-Sildenafil) Reduces Weight in Obese Subjects: A 24-Week Randomized Trial

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Properties of pramlintide and insulin upon mixing

American journal of health-system pharmacy, 2005-04, Vol.62 (8), p.816-822

2005

Volltextzugriff (PDF)

Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue

Diabetes care, 1995-08, Vol.18 (8), p.1179

1995

Volltextzugriff (PDF)

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

Diabetic medicine, 2004-11, Vol.21 (11), p.1204-1212

2004

Volltextzugriff (PDF)

758-P: Medical Food (MF) with Butyrate Producing (BP)+Mucin Regulating (MR) Microbes Improves Glucose Control (GC) in T2D

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

Diabetes (New York, N.Y.), 1987-03, Vol.36 (3), p.274

1987

Volltextzugriff (PDF)

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Diabetes care, 2003-11, Vol.26 (11), p.3074-3079

2003

Volltextzugriff (PDF)

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Diabetes care, 2003-03, Vol.26 (3), p.784-790

2003

Volltextzugriff (PDF)

Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: Role of the glucose transport system

Diabetes/metabolism research and reviews, 1988-09, Vol.4 (6), p.543-569

1988

Volltextzugriff (PDF)

Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes

The American journal of medicine, 1981, Vol.70 (1), p.151-168

1981

Volltextzugriff (PDF)

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

Postgraduate medicine, 2013-05, Vol.125 (3), p.136-144

2013

Volltextzugriff (PDF)

Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes

The American journal of medicine, 1985-09, Vol.79 (3), p.12-22

1985

Volltextzugriff (PDF)

Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects

Diabetes care, 1980-09, Vol.3 (5), p.575

1980

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(48)
Adult
(34)
Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Male
(32)
Female
(31)
Middle Aged
(31)
Endocrinology & Metabolism
(18)
Biological And Medical Sciences
(17)
Insulin - Blood
(17)
Aged
(16)
Medical Sciences
(16)
Blood Glucose - Metabolism
(15)
Islet Amyloid Polypeptide
(14)
Blood Glucose - Analysis
(11)
Diabetes Mellitus, Type 1 - Drug Therapy
(11)
Drug Therapy, Combination
(11)
Hypoglycemic Agents - Therapeutic Use
(11)
Insulin - Metabolism
(11)
Amyloid - Adverse Effects
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes

41-LB: Changes in Circulating Metabolites, Including Butyrate, Points to Underlying Mechanism of a Probiotic Intervention That Improves Postprandial Hyperglycemia in Subjects with Type 2 Diabetes

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

135-OR: A Novel Thiazolidinedione (TZD) with Minimal PPAR-γ Activity Maximized for Mitochondrial Pyruvate Carrier (MPC) Modulation: Six-Month Analysis of Glycemia in a 12-Month Nonalcoholic Steatohepatitis (NASH) Study

2046-P: NS-0200 (Leucine-Metformin-Sildenafil) Reduces Weight in Obese Subjects: A 24-Week Randomized Trial

Properties of pramlintide and insulin upon mixing

Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

758-P: Medical Food (MF) with Butyrate Producing (BP)+Mucin Regulating (MR) Microbes Improves Glucose Control (GC) in T2D

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: Role of the glucose transport system

Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes

Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects

Suchergebnisse filtern